Immunosuppressants - Turkey

  • Turkey
  • The Immunosuppressants market in Turkey is predicted to witness a substantial increase in revenue, with projections indicating that it will reach US$60.13m in 2024.
  • Moreover, the market is expected to exhibit a significant annual growth rate (CAGR 2024-2029) of 15.11%, resulting in a market volume of US$121.50m by 2029.
  • When compared globally, United States stands out as the leading revenue generator in this market, with an estimated revenue of US$35,470.00m in 2024.
  • Turkey's increasing focus on healthcare and medical research has led to a growing demand for immunosuppressants in the country.

Key regions: Australia, Germany, United Kingdom, United States, France

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The demand for Immunosuppressants in Turkey has been increasing steadily in recent years.

Customer preferences:
The increasing prevalence of autoimmune diseases and organ transplantation procedures has been the driving force behind the growth of the Immunosuppressants market in Turkey. Patients suffering from autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis require long-term medication to manage their symptoms. Similarly, organ transplant recipients need to take Immunosuppressants to prevent their body from rejecting the transplanted organ.

Trends in the market:
The Immunosuppressants market in Turkey is dominated by branded drugs, with a few generic alternatives available. However, the government's efforts to promote the use of generic drugs are expected to increase the market share of generic Immunosuppressants in the coming years. Additionally, the market is witnessing a shift towards biologic Immunosuppressants, which offer better efficacy and safety profiles compared to traditional Immunosuppressants.

Local special circumstances:
Turkey's healthcare system is a mix of public and private providers, with the government providing universal healthcare coverage to its citizens. However, the system is underfunded, and patients often have to pay out of pocket for expensive medications such as Immunosuppressants. This has led to a growing demand for affordable generic drugs, which is expected to drive the growth of the generic Immunosuppressants market in the country.

Underlying macroeconomic factors:
Turkey's pharmaceutical market is one of the largest in the Middle East and North Africa (MENA) region, with a rapidly growing population and increasing healthcare expenditure. Additionally, the country's strategic location makes it an attractive market for pharmaceutical companies looking to expand their presence in the region. However, the market is highly regulated, with the government setting price controls on drugs and limiting the reimbursement of expensive medications. This has led to a challenging business environment for pharmaceutical companies operating in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)